Skip to content

Novo Nordisk Pays $25M to Settle False Claims Act Allegations

June 14, 2011

A whistleblower’s allegations of illegal off-label marketing of hemostasis management drug, NovoSeven, has prompted Novo Nordisk, Inc. to pay $25 million. “Once approved by the FDA, a manufacturer may not market or promote a drug for any use not specified in its new drug application and approved by the FDA,” says DoJ.  “Such unapproved uses are also known as ‘off-label’ uses.”  The qui tam relators or “whistleblowers” who alerted the federal and state governments to the fraud, will be rewarded with almost $4,000,000.


Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: